Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/30789
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUsta, Mehmet-
dc.contributor.authorAyar, Yavuz-
dc.contributor.authorGöksel, Gültekin-
dc.contributor.authorKaragöz, İsminur Saka-
dc.date.accessioned2023-02-02T07:27:55Z-
dc.date.available2023-02-02T07:27:55Z-
dc.date.issued2020-01-20-
dc.identifier.citationUsta, M. vd. (2020). "Effect of omega-3 polyunsaturated fatty acid supplementation on glycemic control and renal function in type 2 diabetic patients with chronic kidney disease". Acta Medica Mediterranea, 36(2), 821-828.en_US
dc.identifier.issn0393-6384-
dc.identifier.issn2283-9720-
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2020_2_128-
dc.identifier.urihttps://www.actamedicamediterranea.com/archive/2020/medica-2/effect-of-omega-3-polyunsaturated-fatty-acid-supplementation-on-glycemic-control-and-renal-function-in-type-2-diabetic-patients-with-chronic-kidney-disease-
dc.identifier.urihttp://hdl.handle.net/11452/30789-
dc.description.abstractIntroduction: The aim of this study was to evaluate the short-term effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) supplementation on glycemic control and renal function in type 2 diabetic patients with chronic kidney disease. Materials and methods: Twenty-five diabetic patients received medication containing 2 g/day n-3 PUFA orally in addition to standard treatments. Their estimated glomerular filtration rates (eGFR) were <80 mL/min/1.73 m(2). Biochemical values were evaluated before and 3 months after treatment. Results: After three months of supplementation, the changes in serum creatinine, uric acid, eGFR and urinary albumin excretion levels did not reach statistical significance. There was no difference between serum glucose, HbAlC and lipid profile values before and after the n-3 PUFA.supplementation in patients. Only serum albumin significantly increased from 4.10 +/- 0.26 to 4.28 +/- 0.31 g/dL (p=0.016), and systolic blood pressure decreased from 121.4 +/- 14.5 to 116 .6 +/- 14.9 mmHg (p=0.001). Conclusion: Short-term n-3 PUFA supplementation did not affect renal function and glycemic control in patients with type 2 diabetes with chronic kidney disease.en_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectType 2 diabetes mellitusen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectCardiovascular diseaseen_US
dc.subjectOmega-3 polyunsaturated fatty acidsen_US
dc.subjectProteinuriaen_US
dc.subjectRenal functionen_US
dc.subjectBlood-pressureen_US
dc.subjectOmega-3-fatty-acid supplementationen_US
dc.subjectCardiovascular-diseaseen_US
dc.subjectInsulin-resistanceen_US
dc.subjectIga nephropathyen_US
dc.subjectFish-oilen_US
dc.subjectInflammationen_US
dc.subjectBiomarkersen_US
dc.subjectTrialen_US
dc.subjectGeneral & internal medicineen_US
dc.titleEffect of omega-3 polyunsaturated fatty acid supplementation on glycemic control and renal function in type 2 diabetic patients with chronic kidney diseaseen_US
dc.typeArticleen_US
dc.identifier.wos000526121600013tr_TR
dc.identifier.scopus2-s2.0-85083360934tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.identifier.startpage821tr_TR
dc.identifier.endpage828tr_TR
dc.identifier.volume36tr_TR
dc.identifier.issue2tr_TR
dc.relation.journalActa Medica Mediterraneaen_US
dc.contributor.buuauthorErsoy, Alparslan-
dc.contributor.buuauthorErsoy, Canan-
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.relation.collaborationSanayitr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.subject.scopusCardiovascular Disease; Omega 3 Fatty Acid; Fish Oilsen_US
dc.subject.emtreeAlbuminen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeGlucoseen_US
dc.subject.emtreeHemoglobin A1cen_US
dc.subject.emtreeOmega 3 fatty aciden_US
dc.subject.emtreeUric aciden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChronic kidney failureen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeEstimated glomerular filtration rateen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeGlycemic controlen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeKidney functionen_US
dc.subject.emtreeLipid fingerprintingen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeSystolic blood pressureen_US
dc.subject.emtreeUric acid blood levelen_US
dc.subject.emtreeUrinary excretionen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Ersoy_vd_2020.pdf721.52 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons